WO2014068459A3 - Compositions et méthodes de traitement de la douleur et de maladies neurologiques - Google Patents

Compositions et méthodes de traitement de la douleur et de maladies neurologiques Download PDF

Info

Publication number
WO2014068459A3
WO2014068459A3 PCT/IB2013/059637 IB2013059637W WO2014068459A3 WO 2014068459 A3 WO2014068459 A3 WO 2014068459A3 IB 2013059637 W IB2013059637 W IB 2013059637W WO 2014068459 A3 WO2014068459 A3 WO 2014068459A3
Authority
WO
WIPO (PCT)
Prior art keywords
pain
treatment
compositions
methods
neurological diseases
Prior art date
Application number
PCT/IB2013/059637
Other languages
English (en)
Other versions
WO2014068459A2 (fr
Inventor
Mahesh Kandula
Original Assignee
Mahesh Kandula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahesh Kandula filed Critical Mahesh Kandula
Publication of WO2014068459A2 publication Critical patent/WO2014068459A2/fr
Publication of WO2014068459A3 publication Critical patent/WO2014068459A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Abstract

La présente invention concerne des composés de formule (I) ou leurs sels pharmaceutiquement acceptables, ainsi que leurs polymorphes, solvates, énantiomères, stéréo-isomères et hydrates. La présente invention concerne également des compositions pharmaceutiques comprenant une quantité efficace de composés de formule (I); et des méthodes de traitement de la douleur et de maladies neurologiques. Ces compositions peuvent être formulées pour administration par voie orale, buccale, rectale, topique, transdermique, transmuqueuse, intraveineuse, parentérale, ou bien sous forme de sirop ou sous forme injectable. Lesdites compositions peuvent être utilisées pour traiter des crises partielles ou l'apparition de crises, les douleurs neuropathiques diabétiques, les douleurs dorsales et pour d'autres utilisations orthopédiques, mais également pour les migraines, en oncologie, pour des soins postopératoires, en gynécologie, pour la maladie de Creutzfeld-Jakob, la sclérose en plaques, la maladie de Batten, la fibromyalgie, la maladie d'Alzheimer et la sclérose en plaques.
PCT/IB2013/059637 2012-11-01 2013-10-25 Compositions et méthodes de traitement de la douleur et de maladies neurologiques WO2014068459A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4565/CHE/2012 2012-11-01
IN4565CH2012 2012-11-01

Publications (2)

Publication Number Publication Date
WO2014068459A2 WO2014068459A2 (fr) 2014-05-08
WO2014068459A3 true WO2014068459A3 (fr) 2014-12-24

Family

ID=50628191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/059637 WO2014068459A2 (fr) 2012-11-01 2013-10-25 Compositions et méthodes de traitement de la douleur et de maladies neurologiques

Country Status (1)

Country Link
WO (1) WO2014068459A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017085733A2 (fr) * 2015-11-19 2017-05-26 Krisani Biosciences (P) Ltd. Procédé amélioré pour la synthèse de 2,6-xylidine et de ses dérivés
CN105541705B (zh) * 2015-12-31 2019-08-06 山东罗欣药业集团恒欣药业有限公司 一种马来酸氟吡汀化合物的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011117749A1 (fr) * 2010-03-23 2011-09-29 Mahesh Kandula Composé et procédé pour le traitement de la douleur
US20120172421A1 (en) * 2011-08-17 2012-07-05 Krisani Biosciences (P) Ltd 2, 6 xylidine derivatives for the treatment of pain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011117749A1 (fr) * 2010-03-23 2011-09-29 Mahesh Kandula Composé et procédé pour le traitement de la douleur
US20120172421A1 (en) * 2011-08-17 2012-07-05 Krisani Biosciences (P) Ltd 2, 6 xylidine derivatives for the treatment of pain

Also Published As

Publication number Publication date
WO2014068459A2 (fr) 2014-05-08

Similar Documents

Publication Publication Date Title
WO2013175377A3 (fr) Compositions et méthodes pour le traitement de la mucosite
NZ594741A (en) Specific diarylhydantoin and diarylthiohydantoin compounds
WO2013175376A3 (fr) Compositions et méthodes de traitement de la douleur locale
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
WO2014068463A3 (fr) Compositions et procédés de traitement d'une inflammation et de troubles métaboliques
WO2014087307A3 (fr) Compositions et procédés pour le traitement du syndrome métabolique et du diabète
WO2013175359A3 (fr) Compositions et méthodes pour le traitement de la sclérose en plaques
WO2013168006A3 (fr) Compositions et méthodes de traitement de la douleur locale
WO2014091384A3 (fr) Compositions et méthodes pour le traitement de la mucosite
EP2772481A8 (fr) Nouveau composé utilisé comme agoniste des canaux potassiques kcnq, son procédé de préparation et son utilisation
WO2014068459A3 (fr) Compositions et méthodes de traitement de la douleur et de maladies neurologiques
WO2014006529A3 (fr) Compositions et méthodes de traitement de la douleur modérée à aiguë
WO2014195850A3 (fr) Compositions et méthodes de traitement de maladies neurologiques et de troubles neurologiques
WO2014097137A3 (fr) Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques
MX2012007426A (es) Derivados de amino-heteroarilo como bloqueadores de los canales activados por la hiperpolarizacion, controlados por nucleotidos ciclicos.
WO2013167989A3 (fr) Compositions et méthodes de traitement de troubles neurologiques
MX2019006163A (es) Composiciones y metodos para el tratamiento de enfermedades infecciosas orales.
WO2020075023A3 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
WO2014106804A3 (fr) Compositions et procédés de traitement du syndrome métabolique et du diabète
WO2014087323A3 (fr) Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques
WO2013167986A3 (fr) Compositions et méthodes de traitement de l'épilepsie
WO2014068461A3 (fr) Compositions et méthodes de traitement d'une inflammation aiguë
WO2017208088A3 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
WO2015028976A3 (fr) Composés et méthodes de traitement de maladies inflammatoires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13850296

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13850296

Country of ref document: EP

Kind code of ref document: A2